biostudies-literatureUnknown27(5)Skinner MWF. Hoffmann-La Roche Ltd and Chugai Pharmaceutical Co., Ltd<h4>Introduction</h4>Severe haemophilia A (HA) has a major impact on health-related quality of life (HRQoL).<h4>Aim</h4>Assess the impact of emicizumab on HRQoL in persons with severe HA (PwHA) without factor VIII (FVIII) inhibitors in the phase 3 HAVEN 3 and 4 studies.<h4>Methods</h4>This pooled analysis examines the HRQoL of PwHA aged ≥ 18 years treated with emicizumab prophylaxis via Haemophilia-Specific Quality of Life Questionnaire for Adults (Haem-A-QoL) and EuroQoL 5-Dimensions 5-levels (EQ-5D-5L). In particular, changes from baseline in Haem-A-QoL 'Physical Health' (PH) domain and 'Total Score' (TS) are evaluated.<h4>Results</h4>Among 176 evaluable participants, 96 (55%) had received prior episodic treatment and 80 (45%) prophylaxis; 70% had ≥ 1 target joint and 51% had experiencedHaemophilia : the official journal of the World Federation of Hemophilia854-865https://www.ebi.ac.uk/biostudies/studies/S-EPMC8518882biostudies-literatureThe effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.PMC8518882Shapiro ACallaghan MUShima MNegrier CSkinner MWLehle MJimenez-Yuste VLevy GGOldenburg JNiggli MPipe SWvon Mackensen SMahlangu JCampinha-Bacote APaz-Priel IChebon SfalseThe effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.<h4>Introduction</h4>Severe haemophilia A (HA) has a major impact on health-related quality of life (HRQoL).<h4>Aim</h4>Assess the impact of emicizumab on HRQoL in persons with severe HA (PwHA) without factor VIII (FVIII) inhibitors in the phase 3 HAVEN 3 and 4 studies.<h4>Methods</h4>This pooled analysis examines the HRQoL of PwHA aged ≥ 18 years treated with emicizumab prophylaxis via Haemophilia-Specific Quality of Life Questionnaire for Adults (Haem-A-QoL) and EuroQoL 5-Dimensions 5-levels (EQ-5D-5L). In particular, changes from baseline in Haem-A-QoL 'Physical Health' (PH) domain and 'Total Score' (TS) are evaluated.<h4>Results</h4>Among 176 evaluable participants, 96 (55%) had received prior episodic treatment and 80 (45%) prophylaxis; 70% had ≥ 1 target joint and 51% had experienced2021-01-01T00:00:00Z2021 Sep2026-07-16T16:03:12.39Z2026-07-09T11:07:34.98ZS-EPMC85188823417115910.1111/hae.14363